{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/peripheral-arterial-disease/management/acute-limb-ischaemia/","result":{"pageContext":{"chapter":{"id":"fb3fcf0a-56a8-5693-b5ef-75e12c6f1f11","slug":"acute-limb-ischaemia","fullItemName":"Scenario: Acute limb ischaemia","depth":2,"htmlHeader":"<!-- begin field 13afde42-be81-4950-b947-c6dcb2906a9c --><h2>Scenario: Acute limb ischaemia</h2><!-- end field 13afde42-be81-4950-b947-c6dcb2906a9c -->","summary":"Covers the management and follow up of a person with an acutely ischaemic limb.","htmlStringContent":"<!-- begin item 9267d20d-ee94-461d-a045-5b75632855b3 --><!-- begin field e0e5558e-365a-4531-b55f-acbd0088ea7a --><p>From age 18 years onwards.</p><!-- end field e0e5558e-365a-4531-b55f-acbd0088ea7a --><!-- end item 9267d20d-ee94-461d-a045-5b75632855b3 -->","topic":{"id":"fff7e03a-2313-5ab5-b744-9c6bba67aa6b","topicId":"deeaf796-d620-42bf-903e-a43ff99b1d1d","topicName":"Peripheral arterial disease","slug":"peripheral-arterial-disease","lastRevised":"Last revised in September 2019","chapters":[{"id":"9e988871-ea98-52a6-bb9d-910e22b3a6dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81e6bfaf-7c78-52e2-b11d-8e2315ebe9e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fee65eb3-86d0-571b-9815-f9407ec29fa7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"239ddbef-73a4-5941-9dc8-52d73689e140","slug":"changes","fullItemName":"Changes"},{"id":"39825e21-a7b7-573c-86a7-fd5d87a847d3","slug":"update","fullItemName":"Update"}]},{"id":"da348d6d-4102-5de5-b9be-d28e7c83e8d0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f3f64c-323d-5c10-b5ff-9df793eab0d8","slug":"goals","fullItemName":"Goals"},{"id":"504b7741-50ac-5c4c-ac51-ea56d8cc4c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a7e09ccb-6701-5658-a01c-52a02d7f9f80","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a54b63f6-0b42-5584-91e8-027e613f7246","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f6168c43-2e36-5e1d-bb44-04674d098b73","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"67399dd0-adb5-5b36-a616-cfc0605ebe52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9c30093e-b7fa-5c0f-84d0-465bf0768823","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8f766fdc-ff98-5227-9d99-fe65802aaaca","slug":"definition","fullItemName":"Definition"},{"id":"4c33be40-568c-527a-8936-a79726b11e66","slug":"causes","fullItemName":"Causes"},{"id":"b8817533-a2e9-531b-9c51-d1c3da17b2ef","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ea6fdfd8-a5f7-52de-ac19-8a05fd53556f","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cdbbc165-3643-5f50-8f32-9fc5504ba2ef","slug":"complications","fullItemName":"Complications"},{"id":"59787aa9-8de0-5efd-b54e-2d72c75845a5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"59e978dc-e4bc-574d-a047-413f87ec6b3d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ea4a531c-cf38-5e54-85d9-1f845bf7582f","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"ebe23574-b6e5-5812-816c-6955392cee34","slug":"assessment","fullItemName":"Assessment"},{"id":"c501646c-c9a8-5372-ae9c-c0aab453c6e5","slug":"features-of-acute-limb-ischaemia","fullItemName":"Features of acute limb ischaemia"},{"id":"fdc33cb6-26a1-58c3-8eab-79d69745d871","slug":"features-of-intermittent-claudication-critical-limb-ischaemia","fullItemName":"Features of intermittent claudication and critical limb ischaemia"},{"id":"8c98aa45-6aef-5b47-a997-e9eeec827356","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04fcdfca-c3cb-56b4-a18e-535c5a54e1a9","fullItemName":"Management","slug":"management","subChapters":[{"id":"fb3fcf0a-56a8-5693-b5ef-75e12c6f1f11","slug":"acute-limb-ischaemia","fullItemName":"Scenario: Acute limb ischaemia"},{"id":"d89d9e21-f892-533e-a3b8-e5649a205398","slug":"critical-limb-ischaemia","fullItemName":"Scenario: Critical limb ischaemia"},{"id":"357ee79f-9fa4-57e7-abd7-7881201f1629","slug":"intermittent-claudication","fullItemName":"Scenario: Intermittent claudication"}]},{"id":"da28584d-59b4-5a06-9357-9484a9bf93cc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e3ab00c1-43b9-58c7-a1c4-44198627e4ab","slug":"naftidrofuryl-oxalate","fullItemName":"Naftidrofuryl oxalate"},{"id":"bb79b6c3-de22-58b3-9244-5ae82a6133ad","slug":"paracetamol-weak-opioids","fullItemName":"Paracetamol and weak opioids"}]},{"id":"1545d985-832b-5a4a-abc9-bd7f0c21b754","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"049d6682-f78d-5c05-bdfb-1dbd5e91b017","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"58d7e6c5-f97f-507d-b627-87ab85bde479","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"574b8e96-33b9-5191-81dd-f415c704abf9","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3df8039-73c2-5c30-b7e8-2566977e32dc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d466274b-a2ab-58f1-badc-abfed7066e4f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaed3513-3a59-5991-8410-2c4446539abd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74346084-c291-5a06-ac3d-a0ae85243940","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"04fcdfca-c3cb-56b4-a18e-535c5a54e1a9","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fd1e4b3b-1ccb-57b7-8012-45fbf5697549","slug":"management-of-acute-lower-limb-ischaemia","fullItemName":"Management of acute lower limb ischaemia","depth":3,"htmlHeader":"<!-- begin field bf7a0790-f89a-416f-b641-fd0eb6758020 --><h3>How should I manage acute lower limb ischaemia?</h3><!-- end field bf7a0790-f89a-416f-b641-fd0eb6758020 -->","summary":null,"htmlStringContent":"<!-- begin item e509245f-8e19-40ab-a1b4-f9edce4d6986 --><!-- begin field 030200b9-4d53-4b1f-bff6-a259c4274612 --><ul><li><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/diagnosis/features-of-acute-limb-ischaemia/\">acute limb ischaemia</a> is suspected, arrange emergency assessment by a vascular specialist.</strong></li></ul><!-- end field 030200b9-4d53-4b1f-bff6-a259c4274612 --><!-- end item e509245f-8e19-40ab-a1b4-f9edce4d6986 -->","subChapters":[{"id":"abc2e66e-3a67-5d78-9582-3a58764ed505","slug":"secondary-care-management","fullItemName":"Secondary care management","depth":4,"htmlHeader":"<!-- begin field 4fe82f28-6e6f-48bd-ba0c-e1aebdf963cc --><h4>Secondary care management</h4><!-- end field 4fe82f28-6e6f-48bd-ba0c-e1aebdf963cc -->","summary":null,"htmlStringContent":"<!-- begin item 939e0d37-5aa8-408b-af97-86f69c27361c --><!-- begin field fb921c9c-9de0-443d-835e-af078e5379a8 --><ul><li><strong>Secondary care management will depend on the type of occlusion </strong>(thrombosis or embolus), location, duration of ischaemia, neurological deficit, co-morbidities, type of conduit (artery or graft), the risks of treatment, and the viability of the limb. </li><li><strong>Interventions include:</strong><ul><li>Endovascular therapies, for example:<ul><li>Percutaneous catheter-directed thrombolytic therapy.</li><li>Percutaneous mechanical thrombus extraction.</li></ul></li><li>Surgical interventions, for example:<ul><li>Surgical thromboembolectomy.</li><li>Endarterectomy.</li><li>Bypass surgery.</li><li>Amputation if the limb is unsalvageable.</li></ul></li></ul></li></ul><!-- end field fb921c9c-9de0-443d-835e-af078e5379a8 --><!-- end item 939e0d37-5aa8-408b-af97-86f69c27361c -->","subChapters":[]},{"id":"eabab47c-7757-53e6-b549-ce583a743344","slug":"basis-for-recommendation-a5f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a3df73de-d689-4a87-b5ce-fecbe276f087 --><h4>Basis for recommendation</h4><!-- end field a3df73de-d689-4a87-b5ce-fecbe276f087 -->","summary":null,"htmlStringContent":"<!-- begin item a5fa4417-9500-41c1-a962-948cb5184d4f --><!-- begin field c8639f3c-f1cc-4824-b0dc-139b9a3277b5 --><h5>Referral</h5><ul><li>The recommendation to arrange emergency assessment by a vascular specialist for a person with suspected acute limb ischaemia reflects North American guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Santistevan, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Firnhaber and Powell, 2019</a>]:  <ul><li>Acute limb ischaemia is a medical emergency and people with acute limb ischaemia should undergo rapid evaluation by a vascular specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>].  </li><li>Skeletal muscle will only tolerate ischaemia for 4–6 hours and the longer symptoms of pain and function loss are present, the more remote the possibility of salvaging the limb [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>].<strong> </strong>Re-establishing blood flow is therefore urgently required when acute limb ischaemia is present [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Wennberg, 2013</a>].  </li></ul></li></ul><h5>Secondary care interventions</h5><ul><li>This information is based on a European guideline on the diagnosis and treatment of peripheral arterial diseases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Santistevan, 2017</a>]. </li></ul><!-- end field c8639f3c-f1cc-4824-b0dc-139b9a3277b5 --><!-- end item a5fa4417-9500-41c1-a962-948cb5184d4f -->","subChapters":[]}]},{"id":"fca8cf50-1cd2-59ff-b224-bebd8e992fcd","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field dce01101-1cd3-4c47-b6ad-3de31a091b2c --><h3>How should I follow up someone after hospital treatment for an acutely ischaemic limb?</h3><!-- end field dce01101-1cd3-4c47-b6ad-3de31a091b2c -->","summary":null,"htmlStringContent":"<!-- begin item 87a3c3eb-5dfa-402f-89ed-5a8e69c97620 --><!-- begin field 24b112f3-1996-47c6-aeee-ae3d222a6b6f --><ul><li><strong>Ensure that the person has been offered appropriate follow up depending on the cause of their acute limb ischaemia.</strong></li><li>For people with peripheral arterial disease, offer information, advice, support, and treatment regarding the secondary prevention of cardiovascular disease.<ul><li>For more information on the management of cardiovascular risk, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li>For more detailed information, particularly in relation to:<ul><li>Smoking cessation — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li>Diet, weight management, and exercise — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li>Lipid modification and statin therapy — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>.</li><li>The prevention, diagnosis, and management of diabetes — see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li><li>The prevention, diagnosis, and management of high blood pressure — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>Antiplatelet therapy — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>.</li></ul></li></ul></li></ul><!-- end field 24b112f3-1996-47c6-aeee-ae3d222a6b6f --><!-- end item 87a3c3eb-5dfa-402f-89ed-5a8e69c97620 -->","subChapters":[{"id":"a9402765-ac20-5762-a50a-94d235d410ae","slug":"basis-for-recommendation-a34","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f794860b-3f6f-40dc-9640-358ecfd8f134 --><h4>Basis for recommendation</h4><!-- end field f794860b-3f6f-40dc-9640-358ecfd8f134 -->","summary":null,"htmlStringContent":"<!-- begin item a34241ea-4f9a-47ae-b82d-c4d5078f1a35 --><!-- begin field 873b4bf2-febf-4368-9b18-932cb6a8428a --><h5>Follow up depending on cause of acute limb ischaemia</h5><ul><li>This recommendation is pragmatic and based on what CKS considers to be good clinical practice. </li></ul><h5>Cardiovascular risk factor management in people with peripheral arterial disease</h5><ul><li>The recommendation to start appropriate secondary prevention measures for cardiovascular disease in people with a history of acute limb ischaemia with identified peripheral arterial disease is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Jaffery et al, 2011</a>]. </li><li>UK, European, North American, and international guidelines emphasise the importance of cardiovascular risk factor management for people with peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">NICE, 2012b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2019</a>]. A UK cohort study suggests the careful management of risk factors for peripheral arterial disease in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Cea-Soriano et al, 2018</a>].  </li><li>Managing cardiovascular risk in a person with peripheral arterial disease is recommended because, even in the absence of symptoms, it indicates an increased risk of potentially preventable cardiovascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>]. Even people with asymptomatic peripheral arterial disease are at risk of progression to critical limb ischaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Cea-Soriano et al, 2018</a>].  </li><li>CKS does not recommend formal cardiovascular risk assessment because any person with peripheral arterial disease already has established cardiovascular disease, therefore is considered to be at high risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Joint Formulary Committee, 2019</a>].</li><li>For more information on the evidence for modifying risk factors to decrease the risk of cardiovascular disease, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a></li></ul><h5>Smoking</h5><ul><li>Smoking cessation is a vital part of care for people with peripheral arterial disease who are still smoking and they should be advised to quit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>]. </li><li>Smoking cessation reduces cardiovascular risk. Excess cardiovascular risk is halved within one year of cessation, and the risk is the same as for a non smoker within 5 years of quitting. There is a lack of evidence specifically on the impact of smoking cessation on peripheral arterial disease of the limb, but observational studies suggest benefit in terms of walking distance and amputation rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>].</li><li>Outcomes for people with peripheral artery disease that continue smoking are persistently worse, with an increased likelihood of claudication and critical limb ischaemia, and a two-fold increased risk of limb amputation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Foley et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>]. </li></ul><h5>Diet, weight management, and exercise</h5><ul><li>Diet and weight management are recommended as strategies to manage cardiovascular risk factors in people with peripheral arterial disease by UK, European, and international guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">NICE, 2012b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Aboyans et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2019</a>].  </li><li>Exercise has proven cardiovascular benefit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>].</li></ul><h5>Lipid modification</h5><ul><li>In people with atherosclerosis, treatment of dysplipidaemia lessens the likelihood of adverse cardiovascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2015</a>].  </li><li>Evidence shows that lowering cholesterol with a statin reduces cardiovascular events in people with peripheral arterial disease. Evidence also suggests that statins may have a role in stabilizing atherosclerotic plaques [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>]. Statin therapy also improves limb outcomes in people with peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>].  </li></ul><h5>Diabetes</h5><ul><li>North American guidelines advocate regular follow up and communication between the healthcare providers of a person with diabetes mellitus and peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>].  </li><li>In people with diabetes and peripheral arterial disease, there is an increased risk of adverse outcomes (for example progression to critical limb ischaemia and amputation) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>].  </li><li>The incidence and prevalence of peripheral arterial disease increases with the duration of type 1 and type 2 diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>]. There is evidence that glycaemic control is particularly important for people with diabetes mellitus and peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Gerhard-Herman et al, 2017</a>]. The treatment of diabetes may reduce the risk of microvascular disease and neuropathy, which is particularly relevant to people with peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Kullo and Rooke, 2016</a>]. </li></ul><h5>Hypertension</h5><ul><li>Management of hypertension lowers cardiovascular risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>].  </li><li>Hypertension is associated with a three-fold increased risk of peripheral arterial disease, and there is evidence that treatment of hypertension reduces the rate of stroke and cardiovascular deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>]. Despite the strong association between hypertension and cardiovascular disease, including peripheral arterial disease, the relative risk is not as great as for smoking or diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Conte et al, 2015</a>].  </li></ul><h5>Antiplatelet agents</h5><ul><li>Antiplatelet treatments lessen the risk of major cardiovascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">Morley et al, 2018</a>]. </li><li>Antiplatelet agents (largely aspirin) were found in a meta-analysis to reduce the risk of cardiovascular events by 23% in people with peripheral arterial disease. Evidence from another study found clopidogrel further reduces cardiovascular events compared to aspirin, especially in people with peripheral arterial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/peripheral-arterial-disease/references/\">National Clinical Guideline Centre, 2012</a>].  </li><li>For more information on the evidence for antiplatelet drugs in people with peripheral arterial disease, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>.</li></ul><!-- end field 873b4bf2-febf-4368-9b18-932cb6a8428a --><!-- end item a34241ea-4f9a-47ae-b82d-c4d5078f1a35 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}